...
首页> 外文期刊>Biological psychiatry >Sex differences in Corticotropin-releasing factor receptor-1 action within the dorsal raphe nucleus in stress responsivity
【24h】

Sex differences in Corticotropin-releasing factor receptor-1 action within the dorsal raphe nucleus in stress responsivity

机译:应激反应中背沟核内促肾上腺皮质激素释放因子受体1作用的性别差异

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background Women are twice as likely as men to suffer from stress-related affective disorders. Corticotropin-releasing factor (CRF) is an important link between stress and mood, in part through its signaling in the serotonergic dorsal raphe (DR). Development of CRF receptor-1 (CRFr1) antagonists has been a focus of numerous clinical trials but has not yet been proven efficacious. We hypothesized that sex differences in CRFr1 modulation of DR circuits might be key determinants in predicting therapeutic responses and affective disorder vulnerability. Methods Male and female mice received DR infusions of the CRFr1 antagonist, NBI 35965, or CRF and were evaluated for stress responsivity. Sex differences in indices of neural activation (cFos) and colocalization of CRFr1 throughout the DR were examined. Whole-cell patch-clamp electrophysiology assessed sex differences in serotonin neuron membrane characteristics and responsivity to CRF. Results Males showed robust behavioral and hypothalamic-pituitary-adrenal axis responses to DR infusion of NBI 35965 and CRF, whereas females were minimally responsive. Sex differences were also found for both CRF-induced DR cFos and CRFr1 co-localization throughout the DR. Electrophysiologically, female serotonergic neurons showed blunted membrane excitability and divergent inhibitory postsynaptic current responses to CRF application. Conclusions These studies demonstrate convincing sex differences in CRFr1 activity in the DR, where blunted female responses to NBI 35965 and CRF suggest unique stress modulation of the DR. These sex differences might underlie affective disorder vulnerability and differential sensitivity to pharmacologic treatments developed to target the CRF system, thereby contributing to a current lack of CRFr1 antagonist efficacy in clinical trials.
机译:背景技术女性遭受与压力有关的情感障碍的可能性是男性的两倍。促肾上腺皮质激素释放因子(CRF)是压力与情绪之间的重要联系,部分是通过其在血清素能背缝(DR)中的信号传递来实现的。 CRF受体1(CRFr1)拮抗剂的开发一直是众多临床试验的重点,但尚未被证明有效。我们假设DR电路的CRFr1调节中的性别差异可能是预测治疗反应和情感障碍易感性的关键决定因素。方法雄性和雌性小鼠接受CRFr1拮抗剂,NBI 35965或CRF的DR输注,并评估其应激反应性。检查了整个DR中神经激活指数(cFos)和CRFr1的共定位的性别差异。全细胞膜片钳电生理评估5-羟色胺神经元膜特征和对CRF的反应的性别差异。结果男性对DR注入NBI 35965和CRF表现出强烈的行为和下丘脑-垂体-肾上腺轴反应,而女性反应最小。在整个DR中,也发现了CRF诱导的DR cFos和CRFr1共定位的性别差异。电生理学上,女性血清素能神经元表现出钝化的膜兴奋性和对CRF施加的抑制性突触后电流反应。结论这些研究表明,DR的CRFr1活性存在令人信服的性别差异,其中女性对NBI 35965和CRF的反应迟钝表明DR的独特应激调节。这些性别差异可能是情感障碍的脆弱性和对针对CRF系统开发的药物治疗的敏感性差异,从而导致目前临床试验中缺乏CRFr1拮抗剂功效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号